Immunomedics, Inc

Immunomedics, Inc. (NASDAQ:IMMU) Presents Promising Data Of Sacituzumab Govitecan For Treatment Of Metastatic Breast Cancer In Women

Immunomedics, Inc. (NASDAQ:IMMU) has announced promising data of Sacituzumab Govitecan, a single agent appropriate for treatment of metastatic breast cancer (mBC). The study findings indicate that the lead investigational ADC conducted on the heavily pre-treated patients with estrogen receptor-positive or human epidermal growth factor receptor 2-negative shows promising responses.

The Sacituzumab Govitecan could be the best available treatment for ER+/HER2 categories thus becoming the leading foundational therapy for metastatic breast cancer. According to the findings, the treatment of Sacituzumab govitecan was well tolerated and there are no reported deaths.

New Opportunities for The Company

The company recently was invited to present its new findings on Sacituzumab Govitecan at the 2018 ASCO Meeting, which will be held on June 1-5, 2018 at the McCormick Place Convention Center, Chicago, Illinois.

According to Robert Iannone, M.D., M.S.C.E, Head of Research & Development and CCO at Immunomedics, the opportunity to present the promising data at the oncoming conference will give the company a chance to market its new product and further explore better treatment alternatives for patients with a dire need for better and affordable treatment options.

According to Iannone, the company is planning to implement its first breast cancer signal in patients diagnosed with metastatic triple-negative breast cancer. The firm will submit its application for Biologic License to the Food and Drug Administration before the end of May 2018 for approval in the next third-line set up.

Breast Cancer, a Killer Disease

Breast cancer has increasingly become the number one killer of women in the whole world and Immunomedics is focusing on developing improved therapies to combat the menace. The company is currently planning to submit its Biologics License Application to the Food and Drug Administration (FDA) before the end of May 2018 in order to obtain approvals for development and distribution of sacituzumab govitecan.

Aditya Bardia, MD., MPH., Director of Precision Medicine and Physician at the Center for Breast Cancer for several hospitals across the country is impressed with the progress of Immunomedics on the development of sacituzumab govitecan to treat the most vulnerable subgroup of patients with metastatic breast cancer. The current treatment options are limited and costly.

Immunomedics is a clinical-stage biopharmaceutical company focusing on the development of antibody-related products for the treatment of cancer and other chronic medical conditions. Immunomedics intends to commercialize its foremost advanced product candidate, sacituzumab govitecan in the US.

More Articles:

https://finance.yahoo.com/news/immunomedics-announces-promising-data-sacituzumab-210100145.html?guccounter=1

https://globenewswire.com/news-release/2018/04/25/1487401/0/en/Immunomedics-Announces-Oral-Presentation-of-Sacituzumab-Govitecan-in-Hormone-Receptor-Positive-HR-Metastatic-Breast-Cancer-mBC-at-2018-American-Society-of-Clinical-Oncology-ASCO-An.html